Westwood Wealth Management Acquires Shares of 29,234 Pfizer Inc. $PFE

Westwood Wealth Management acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) in the fourth quarter, HoldingsChannel.com reports. The fund acquired 29,234 shares of the biopharmaceutical company’s stock, valued at approximately $728,000.

Other hedge funds also recently made changes to their positions in the company. Fiduciary Alliance LLC lifted its holdings in Pfizer by 46.4% in the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock worth $3,701,000 after buying an additional 46,043 shares during the period. Y Intercept Hong Kong Ltd bought a new position in shares of Pfizer during the third quarter valued at approximately $3,019,000. Vista Investment Partners LLC raised its holdings in shares of Pfizer by 236.1% during the third quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock valued at $1,774,000 after acquiring an additional 48,900 shares in the last quarter. Money Concepts Capital Corp lifted its stake in Pfizer by 29.9% in the third quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock worth $6,325,000 after acquiring an additional 57,188 shares during the period. Finally, Kepler Cheuvreux Suisse SA bought a new stake in Pfizer in the third quarter valued at $16,613,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of PFE opened at $28.37 on Friday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $28.75. The firm’s 50-day simple moving average is $27.09 and its two-hundred day simple moving average is $25.83. The stock has a market cap of $161.29 billion, a PE ratio of 20.86 and a beta of 0.43. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. During the same period in the previous year, the firm posted $0.63 EPS. The business’s revenue for the quarter was down 1.2% compared to the same quarter last year. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PFE has been the topic of a number of research analyst reports. Bank of America reduced their price objective on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. TD Cowen reissued a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price for the company. in a research note on Thursday, February 12th. Finally, Guggenheim lifted their price target on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus price target of $28.19.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.